Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the…
BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular…